According to a new research report “Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 74 drug candidates.
ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.
Insights on pipeline analysis
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route.
Chemical Genomics-Based Discovery Platform for ER+ breast cancer drug development
Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.
Major companies collaborate for the development of ER+ breast cancer pipeline
The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.
ER+ Breast Cancer Pipeline Analysis